Haemonetics Corporation

HAE Healthcare Medical Devices

Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025. In the quarter to June 2026, revenue grew 5.60%, EPS grew 2.86%, free cash flow grew 220.4% and total debt rose 27.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

118.28 3.01 −2.48%
Market cap
$5.5B
P/E
57.7×
Fwd P/E
18.0×
Dividend yield
—
F-score
6/9
Altman Z
2.21
Beneish M
−2.81
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
11.20% 12.03% 19.30% 19.47%

+8 more TTM periods

Piotroski F-Score
7 6 7 7
ROA
3.99% 4.02% 6.99% 6.77%
ROIC
5.62% 5.53% 10.69% 10.30%
Return on Tangible Assets
11.31% 11.34% 25.03% 26.12%
Average Days of Receivables
58.33 59.33 54.19 56.92
Free Cash Flow per Share
6.45 5.55 6.65 5.45
Free Cash Flow
292.53 261.82 311.38 259.20
Other line items

Show all line items

Columns are period end dates